Composition including, as active ingredient, strain having ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity

Patent metadata

Field	Value
Publication number	US-11564955-B2
Application number	US-201716462901-A
Country	US
Kind code	B2
Filing date	Nov 21, 2017
Priority date	Nov 21, 2016
Publication date	Jan 31, 2023
Grant date	Jan 31, 2023

Abstract

The present invention relates to a composition comprising as an active ingredient a strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity; and to a food composition and a health functional food each comprising the active ingredient. The strain having excellent ability to produce formic acid according to the present invention not only has effects of reducing body weight and inhibiting fat accumulation in organs, but also has activity to effectively lower blood triglyceride and cholesterol levels, and therefore, the composition comprising the strain as an active ingredient can be favorably used as a composition capable of preventing/alleviating or treating obesity or metabolic syndromes caused by obesity. Therefore, the strain having excellent ability to produce formic acid according to the present invention can be favorably used as a material for a medical product or health food.

First claim

The invention claimed is:

1. A method of preventing or treating metabolic syndrome in a mammal in need thereof, said method comprising:
administering to the mammal in need thereof a strain having formic acid producing ability,
wherein the strain is at least one species selected from the group consisting of Enterococcus faecium KR127 (accession number: KCTC 13135 BP), Pediococcus pentosaceus NKR654 (accession number: KCTC 1313 7 BP), and Enterococcus faecalis TN3 (accession number: KCTC 13136 BP).

2. The method of claim 1 , wherein the metabolic syndrome is selected from the group consisting of obesity, diabetes, arteriosclerosis, hypertension, hyperlipidemia, liver diseases, stroke, myocardial infarction, ischemic diseases, and cardiovascular diseases.

3. The method of claim 1 , wherein the strain is administered in a composition in a content of 10 7 -10 12 cfu/g relative to a total weight of the composition.

Assignees

• Korea Food Res Inst

Inventors

• Lee Myung Ki
• Lim Sang Dong
• Yi Sung Hun
• Cho Yong Sun
• Nam Young Do
• Bae Jin Ju

Classifications

• A61K35/744 Primary

  Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs · CPC title

• A23L33/135 Primary

  Bacteria or derivatives thereof, e.g. probiotics · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A23V2200/326

  having effect on cardiovascular health · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title